Acute pain management in opioid-tolerant patients: A growing challenge

Anaesthesia and Intensive Care

Volumn 39, Issue 5, 2011, Pages 804-823

  Huxtable, C A ^a   Roberts, L J ^c   Somogyi, A A ^b   Macintyre, P E ^b,d  

^a ROYAL ADELAIDE HOSPITAL   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Acute pain; Analgesics; Buprenorphine; Drug addiction; Drug tolerance; Methadone; Opioid analgesics; Opioid substitution treatment; Opioid tolerant; Perioperative period; Postoperative pain; Suboxone

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CLONIDINE; COCODAMOL; CODEINE; ILLICIT DRUG; KETAMINE; METHADONE; MORPHINE; NALOXONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PARACETAMOL; PENTAZOCINE; PETHIDINE; TARGIN; TRAMADOL; UNCLASSIFIED DRUG;

ANALGESIA; CANCER PAIN; CHRONIC NON CANCER PAIN; CHRONIC PAIN; DRUG EFFICACY; DRUG TOLERANCE; DYSPHORIA; HALLUCINATION; HOSPITAL DISCHARGE; HUMAN; INTRAVENOUS REGIONAL ANESTHESIA; LONG TERM CARE; MAINTENANCE THERAPY; NONHUMAN; OPIATE ADDICTION; OUTCOME ASSESSMENT; PAIN; PAIN ASSESSMENT; PATIENT CONTROLLED ANALGESIA; PATIENT MONITORING; POSTOPERATIVE PAIN; PRESCRIPTION; PREVALENCE; REVIEW; RISK FACTOR; WITHDRAWAL SYNDROME;

EID: 80053031676     PISSN: 0310057X     EISSN: 14480271     Source Type: Journal    
DOI: 10.1177/0310057x1103900505     Document Type: Review

References (156)

1. Ballantyne JC, LaForge K Steven. Opioid dependence and addiction during opioid treatment of chronic pain. Pain 2007; 129:235-255. (Pubitemid 46754581)
2. Jamison RN, Kauffman J, Katz NP. Characteristics of methadone maintenance patients with chronic pain. J Pain Symptom Manage 2000; 19:53-62. (Pubitemid 30067624)
3. United Nations Office on Drugs and Crimes. World Drug Report 2010. From http://www.unodc.org/unodc/en/data-and-analysis/WDR-2010.html Accessed January 2011.
4. International Narcotics Control Board. Narcotic drugs - technical reports. Estimated world requirements for 2011 - Statistics for 2009 From http://www.incb.org/incb/narcotic-drugs-reports.html Accessed January 2011.
5. Royal Australasian College of Physicians. Prescription opioid policy: improving management of chronic non-maligant pain and prevention of problems associated with precription opioid use. From http://www.racp.edu.au/page/policy- and-advocacy/ Accessed January 2011.
6. Leong M, Murnion B, Haber PS. Examination of opioid prescribing in Australia from 1992 to 2007. Intern Med J 2009; 39:676-681.
7. Australian Bureau of Statistics. Australian demographic statistics: Population change, summary - Australia ('000). From http://www.abs.gov.au/ AUSSTATS/abs@.nsf/DetailsPage/3101.0Mar%202010?OpenDocument Accessed March 2011.
8. Australian Government Department of Health and Aging. Public summary document: fentanyl transdermal patch. From http://www.health.gov.au/internet/ main/publishing.nsf/Content/pbac-psd-fentanylpatch-mar06. Accessed January 2011.
9. Pharmaceutical Management Agency of New Zealand. From http://www.pharmac.govt.nz/ Accessed January 2011.
10. Sheridan J, Butler R. University of Auckland, Faculty of Medical and Health Sciences. Prescription drug misuse: issues for primary care final report of findings. From http://ndp.govt.nz/moh.nsf/pagescm/7540/$File/ prescription-drug-misuse-primary-care-2008v2.pdf Accessed March 2011.
11. Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician 2010; 13:401-435.
12. MBF Foundation. The high price of pain: the economic impact of persistent pain in Australia. From http://www.mbf.com.au/MBF/About%20MBF/Forms/MBF- Foundation-the-price-of-pain.pdf Accessed March 2011.
13. Blyth FM, March LM, Brnabic AJM, Jorm LR, Williamson M, Cousins MJ. Chronic pain in Australia: a prevalence study. Pain 2001; 89:127-134. (Pubitemid 32146391)
14. Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 2008; 9:444-459. (Pubitemid 351722518)
15. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10:113-130.
16. Faculty of Pain Medicine ANZCA. PM 1: Principles regarding the use of opioid analgesics in patients with chronic non-cancer pain. From http://www.anzca.edu.au/fpm/resources/professional-documents/PM1%202010.pdf Accessed March 2011.
17. Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010; CD006605.
18. Manchikanti L, Ailinani H, Koyyalagunta D, Datta S, Singh V, Eriator I et al. A systematic review of randomized trials of long-term opioid management for chronic non-cancer pain. Pain Physician 2011; 14:91-121.
19. Manchikanti L, Vallejo R, Manchikanti KN, Benyamin RM, Datta S, Christo PJ. Effectiveness of long-term opioid therapy for chronic non-cancer pain. Pain Physician 2011; 14:E133-156.
20. Smith HS, Kirsh KL, Passik SD. Chronic opioid therapy issues associated with opioid abuse potential. J Opioid Manag 2009; 5:287-300.
21. Heit HA, Gourlay DL. Tackling the difficult problem of prescription opioid misuse. Ann Intern Med 2010; 152:747-748.
22. Solanki DR, Koyyalagunta D, Shah RV, Silverman SM, Manchikanti L. Monitoring opioid adherence in chronic pain patients: assessment of risk of substance misuse. Pain Physician 2011; 14:E119-31.
23. Australian Institute of Health and Welfare. Cancer in Australia 2010: an overview. From http://www.aihw.gov.au/publication-detail/?id=6442472459&tab= 1 Accessed March 2011.
24. King T, Porreca F. Opioids in cancer pain: new considerations. IASP Pain Clinical Updates 2010; 18:1-5.
25. Australian Institute of Health and Welfare. National opioid pharmacotherapy statistics annual data collection: 2009 Report. From http://www.aihw.gov.au/publication-detail/?id=6442468365 Accessed March 2011.
26. New Zealand Ministry of Health. New Zealand Clinical Guidelines for the Use of Buprenorphine (with or without Naloxone) in the Treatment of Opioid Dependence 2010. From http://www.moh.govt.nz/moh.nsf/indexmh/nz-guidelines- buprenorphine-2010 Accessed March 2010.
27. Australian Government Department of Health and Ageing National Drugs Strategy. National pharmacotherapy policy for people dependent on opioids. From http://www.health.gov.au/internet/drugstrategy/publishing.nsf/Content/ pharmacotherapy Accessed March 2011.
28. Larance B, Degenhardt L, Mattick RP, O'Brien S, Lintzeris N, Bell J et al. (2009) The diversion and injection of the pharmaceutical opioids used in opioid substitution treatment: Findings from the Australian post-marketing surveillance studies of buprenorphine-naloxone, 2006-2008. From http://ndarc.med.unsw.edu.au/NDARCWeb.nsf/resources/TR+298-302/$file/ TR+302.pdf National Drug and Research Centre. Accessed March 2010.
29. Ballantyne JC. U.S. opioid risk management initiatives. IASP Pain Clinical Updates 2009; 17:1-5.
30. Australian Institute of Health and Welfare. 2007 National drug strategy household survey. From http://www.aihw.gov.au/publication-detail/?id= 6442468195&tab=1 Accessed March 2011.
31. Stafford J, Burns L. National Drug and Alcohol Research Centre, University of New South Wales. Australian Drug Trends 2009: Findings from the Illicit Drug Reporting System (IDRS). From http://ndarc.med.unsw.edu.au/ NDARCWeb.nsf/resources/DRUG-TRENDS-1-NAT/$file/DT2009.pdf Accessed January 2011.
32. Breen C, Degenhardt L, Roxburgh A, Bruno R, Duquemin A, Fetherston J et al. National Drug and Alcohol Research Centre, University of New South Wales Australian Drug Trends 2002: Findings from the Illicit Drug Reporting System (IDRS). From http://ndarc.med.unsw.edu.au/NDARCWeb.nsf/resources/Mono-6/ $file/Mono.50.pdf Accessed March 2011.
33. Stafford J, Degenhardt L, Black E, Bruno R, Buckingham K, Fetherston J et al. National Drug and Alcohol Research Centre, University of New South Wales. Australian Drug Trends 2005: Findings from the Illicit Drug Reporting System (IDRS). From http://ndarc.med.unsw.edu.au/NDARCWeb.nsfresources/Mono-1/ $file/Mono.59.pdf Accessed March 2011.
34. National Centre in HIV Epidemiology and Clinical Research, University of New South Wales. Sydney Medically Supervised Injecting Centre Evaluation Report No. 4: Evaluation of service operation and overdose-related events. From http://www.med.unsw.edu.au/NCHECRweb.nsf/resources/Interim-eval-rep-2/ $file/EvalRep4SMSIC.pdf Accessed March 2011.
35. New Zealand Drug Foundation. Into my arms: Injecting drug use in New Zealand. From http://www.drugfoundation.org.nz/matters-of-substance/into-my- arms. Accessed March 2011.
36. Wilkins C, Casswell S, Bhatta B, Pledger M. Alcohol & Public Health Research Unit, Faculty of Medicine and Health Science, University of Auckland. Drug use in New Zealand: national surveys comparison 1998 & 2001. From http://www.aphru.ac.nz/projects/drugs%202001%20TC.htm Accessed March 2011.
37. New Zealand Ministry of Health. National Drug Policy 2007-2012. From http://www.ndp.govt.nz/moh.nsfpagescm/685/$File/ nationaldrugpolicy20072012.pdf Accessed March 2011.
38. Substance Abuse and Mental Health Services Administration. Highlights of the 2009 Drug Abuse Warning Network (DAWN) Findings on drug-related emergency department visits. From http://www.oas.samhsa.gov/2k10/DAWN034/EDHighlightsHTML. pdf Accessed March 2011.
39. Australian Institute of Health and Welfare. National Hospital Morbidity Database. From http://www.aihw.gov.au/hospitals/nhm-database.cfm Accessed January 2011.
40. Bohnert AS, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011; 305:1315-1321.
41. Rintoul AC, Dobbin MD, Drummer OH, Ozanne-Smith J. Increasing deaths involving oxycodone, Victoria, Australia, 2000-09. Inj Prev 2011; 17:254-259.
42. International Association for the Study of Pain. Pain Terminology. From http://www.iasp-pain.org/AM/Template.cfm?Section=Pain-Definitions&Template=/ CM/HTMLDisplay.cfm&ContentID=1728 Accessed March 2011.
43. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 2006; 104: 570-587.
44. Fishbain DA, Cole B, Lewis JE, Gao J, Rosomoff RS. Do opioids induce hyperalgesia in humans? An evidence-based structured review. Pain Med 2009; 10:829-839.
45. Tompkins DA, Campbell CM. Opioid-induced hyperalgesia: clinically relevant or extraneous research phenomenon? Curr Pain Headache Rep 2011; 15:129-136.
46. Mao J. Opioid-induced hyperalgesia. IASP Pain Clinical Updates 2008; 16:1-4.
47. Compton P, Charuvastra VC, Kintaudi K, Ling W. Pain responses in methadone-maintained opioid abusers. J Pain Symptom Manage 2000; 20:237-245.
48. Doverty M, White JM, Somogyi AA, Bochner F, Ali R, Ling W. Hyperalgesic responses in methadone maintenance patients. Pain 2001; 90:91-96. (Pubitemid 32146561)
49. Mitchell TB, White JM, Somogyi AA, Bochner F. Switching between methadone and morphine for maintenance treatment of opioid dependence: impact on pain sensitivity and mood status. Am J Addict 2006; 15:311-315. (Pubitemid 44174493)
50. Compton P, Charuvastra VC, Ling W. Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Depend 2001; 63:139-146. (Pubitemid 32488928)
51. Athanasos P, Smith CS, Ling W, Bochner F, Somogyi AA, White JM. Morphine plus S(+) ketamine or tramadol elicit antinociception in opioid non-tolerant and buprenorphine maintained but not methadone maintained subjects. Abstracts of the 11th World Congress on Pain, International Association for the Study of Pain 2005.
52. Hay JL, White JM, Bochner F, Somogyi AA, Semple TJ, Rounsefell B. Hyperalgesia in opioid-managed chronic pain and opioid-dependent patients. J Pain 2009; 10:316-322.
53. Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain 2006; 7:43-48. (Pubitemid 43097262)
54. Pud D, Cohen D, Lawental E, Eisenberg E. Opioids and abnormal pain perception: new evidence from a study of chronic opioid addicts and healthy subjects. Drug Alcohol Depend 2006; 82:218-223.
55. Chia YY, Liu K, Wang JJ, Kuo MC, Ho ST. Intraoperative high dose fentanyl induces postoperative fentanyl tolerance. Can J Anaesth 1999; 46:872-877. (Pubitemid 29528851)
56. Guignard B, Bossard AE, Coste C, Sessler DI, Lebrault C, Alfonsi P et al. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology 2000; 93:409-417. (Pubitemid 30620314)
57. Mitra S. Opioid-induced hyperalgesia: pathophysiology and clinical implications. J Opioid Manag 2008; 4:123-130.
58. Angst MS, Koppert W, Pahl I, Clark DJ, Schmelz M. Short-term infusion of the mu-opioid aganist remifentanil in humans causes hyperalgesia during withdrawal. Pain 2003; 106:49-57. (Pubitemid 37329613)
59. Koppert W, Sittl R, Scheuber K, Alsheimer M, Schmelz M, Schuttler J. Differential modulation of remifentanil induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans. Anesthesiology 2003; 99:152-159. (Pubitemid 36799046)
60. Angst MS, Chu LF, Tingle MS, Shafer SL, Clark JD, Drover DR. No evidence for the development of acute tolerance to analgesic, respiratory depressant and sedative opioid effects in humans. Pain 2009; 142:17-26.
61. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain 2008; 24:479-496.
62. Christie MJ. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol 2008; 154:384-396. (Pubitemid 351670590)
63. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 2011; 14:145-161.
64. Joly V, Richebe P, Guignard B, Fletcher D, Maurette P, Sessler DI et al. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology 2005;103:147-155. (Pubitemid 40943147)
65. Altier C, Zamponi GW. Opioid, cheating on its receptors, exacerbates pain. Nat Neurosci 2006; 9:1465-1467. (Pubitemid 44862649)
66. King T, Gardell LR, Wang R, Vardanyan A, Ossipov MH, Malan TP Jr et al. Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain 2005; 116:276-288. (Pubitemid 40957131)
67. Crain SM, Shen KF. Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia. Brain Res 2001; 888:75-82. (Pubitemid 32056264)
68. Wang HY, Frankfurt M, Burns LH. High-affinity naloxone binding to filamin a prevents mu opioid receptor-Gs coupling underlying opioid tolerance and dependence. PLoS One 2008; 3:e1554.
69. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009; 10:23-36.
70. Watkins LR, Hutchinson MR, Rice KC, Maier SF. The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci 2009; 30:581-591.
71. Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX et al. Evidence that opioids may have toll-likereceptor 4 and MD-2 effects. Brain Behav Immun 2010; 24:83-95.
72. Roberts LJ. The opioid-tolerant patient, including those with a substance abuse disorder. In: Macintyre PE, Walker SM, Rowbotham DJ, eds. Clinical Pain Management: Acute Pain, 2nd ed. London: Hodder Arnold 2008.
73. Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med 2006; 144:127-134. (Pubitemid 46768231)
74. Macintyre PE, Schug SA, Scott DA, Visser EJ, Walker SM. APM:SE Working Group of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine. Acute Pain Management: Scientific Evidence, 3rd ed. From www.anzca.edu.au/resources/books-and-publications Accessed March 2011.
75. Peng PW, Tumber PS, Gourlay D. Review article: perioperative pain management of patients on methadone therapy. Can J Anaesth 2005; 52:513-523. (Pubitemid 40883313)
76. Hansson KS, Fridlund B, Brunt D, Hansson B, Rask M. The meaning of the experiences of persons with chronic pain in their encounters with the health service. Scand J Caring Sci 2010; [Epub ahead of print].
77. Scimeca MM, Savage SR, Portenoy R, Lowinson J. Treatment of pain in methadone-maintained patients. Mt Sinai J Med 2000; 67:412-422.
78. Mehta V, Langford RM. Acute pain management for opioid dependent patients. Anaesthesia 2006; 61:269-276. (Pubitemid 43337368)
79. Haber PS, Demirkol A, Lange K, Murnion B. Management of injecting drug users admitted to hospital. Lancet 2009; 374:1284-1293.
80. Myles PS, Leslie K, McNeil J, Forbes A, Chan MT. Bispectral index monitoring to prevent awareness during anaesthesia: the B-Aware randomised controlled trial. Lancet 2004; 363:1757-1763. (Pubitemid 38698378)
81. Vereecke HEM, Vanluchene AL, Mortier EP, Everaert K, Struys MM. The effects of ketamine and rocuronium on the A-Line auditory evoked potential index, Bispectral Index, and spectral entropy monitor during steady state propofol and remifentanil anesthesia. Anesthesiology 2006; 105:1122-1134. (Pubitemid 44808576)
82. Prodduturi S, Sadrieh N, Wokovich AM, Doub WH, Westenberger BJ, Buhse L. Transdermal delivery of fentanyl from matrix and reservoir systems: effect of heat and compromised skin. J Pharm Sci 2010; 99:2357-2366.
83. Rapp SE, Ready LB, Nessly ML. Acute pain management in patients with prior opioid consumption: a case-controlled retrospective review. Pain 1995; 61:195-201.
84. Macintyre PE, Schug SA. Acute pain management: a practical guide, 3rd ed. Saunders Elsevier, London 2007.
85. Chapman CR, Donaldson G, Davis J, Ericson D, Billharz J. Postoperative pain patterns in chronic pain patients: a pilot study. Pain Med 2009; 10:481-487.
86. Rapp SE, Wild LM, Egan KJ, Ready LB. Acute pain management of the chronic pain patient on opiates: a survey of caregivers at University of Washington Medical Center. Clin J Pain 1994; 10:133-138. (Pubitemid 24166286)
87. Victorian Quality Council. Acute pain management measurement toolkit. From http://www.health.vic.gov.au/qualitycouncil/downloads/apmm-toolkit.pdf Accessed February 2011.
88. Broyles LM, Colbert AM, Tate JA, Swigart VA, Happ MB. Clinicians' evaluation and management of mental health, substance abuse, and chronic pain conditions in the intensive care unit. Crit Care Med 2008; 36:87-93.
89. Chang G, Chen L, Mao J. Opioid tolerance and hyperalgesia. Med Clin North Am 2007; 91:199-211.
90. Davis JJ, Swenson JD, Hall RH, Dillon JD, Johnson KB, Egan TD et al. Preoperative "fentanyl challenge" as a tool to estimate postoperative opioid dosing in chronic opioid-consuming patients. Anesth Analg 2005; 101:389-395. (Pubitemid 41045219)
91. Hadi I, Morley-Forster PK, Dain S, Horrill K, Moulin DE. Brief review: perioperative management of the patient with chronic non-cancer pain. Can J Anaesth 2006; 53:1190-1199.
92. George JA, Lin EE, Hanna MN, Murphy JD, Kumar K, Ko PS et al. The effect of intravenous opioid patient-controlled analgesia with and without background infusion on respiratory depression: a meta-analysis. J Opioid Manag 2010; 6:47-54.
93. Roberts LJ, Hellier L, Croy H. Opioid tolerance and perioperative pain management. Abstracts of the 11th World Congress on Pain, International Association for the Study of Pain 2005.
94. Maund E, McDaid C, Rice S, Wright K, Jenkins B, Woolacott N. Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs for the reduction in morphine-related side-effects after major surgery: a systematic review. Br J Anaesth 2011; 106:292-297.
95. Bell RF, Dahl JB, Moore RA, Kalso E. Perioperative ketamine for acute postoperative pain. Cochrane Database Syst Rev 2006; CD004603.
96. Zakine J, Samarcq D, Lorne E, Moubarak M, Montravers P, Beloucif S et al. Postoperative ketamine administration decreases morphine consumption in major abdominal surgery: a prospective, randomized, double-blind, controlled study. Anesth Analg 2008; 106:1856-1861.
97. Loftus RW, Yeager MP, Clark JA, Brown JR, Abdu WA, Sengupta DK et al. Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery. Anesthesiology 2010; 113:639-646.
98. Urban MK, Ya Deau JT, Wukovits B, Lipnitsky JY. Ketamine as an adjunct to postoperative pain management in opioid tolerant patients after spinal fusions: a prospective randomized trial. HSS J 2008; 4:62-65.
99. Lin SL, Tsai RY, Shen CH, Lin FH, Wang JJ, Hsin ST et al. Co-administration of ultra-low dose naloxone attenuates morphine tolerance in rats via attenuation of NMDA receptor neurotransmission and suppression of neuroinflammation in the spinal cords. Pharmacol Biochem Behav 2010; 96:236- 245.
100. Wang HY, Friedman E, Olmstead MC, Burns LH. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling. Neuroscience 2005; 135:247- 261.
101. Crain SM, Shen KF. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment. Proc Natl Acad Sci U S A 1995; 92:10540-10544.
102. La Vincente SF, White JM, Somogyi AA, Bochner F, Chapleo CB. Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects. Clin Pharmacol Ther 2008; 83:144-152.
103. Sartain JB, Barry JJ, Richardson CA, Branagan HC. Effect of combining naloxone and morphine for intravenous patient-controlled analgesia. Anesthesiology 2003; 99:148-151. (Pubitemid 36799045)
104. Cepeda MS, Alvarez H, Morales O, Carr DB. Addition of ultralow dose naloxone to postoperative morphine PCA: unchanged analgesia and opioid requirement but decreased incidence of opioid side effects. Pain 2004; 107:41-46. (Pubitemid 38058697)
105. Cepeda MS, Africano JM, Manrique AM, Fragoso W, Carr DB. The combination of low dose of naloxone and morphine in PCA does not decrease opioid requirements in the postoperative period. Pain 2002; 96:73-79. (Pubitemid 34270630)
106. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev 2004; CD004847.
107. Fine PG, Portenoy RK. Establishing "best practices" for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage 2009; 38:418-425.
108. Patanwala AE, Duby J, Waters D, Erstad BL. Opioid conversions in acute care. Ann Pharmacother 2007; 41:255-266.
109. Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic dose ratios for opioids. a critical review and proposals for long-term dosing. J Pain Symptom Manage 2001; 22:672-687. (Pubitemid 32725810)
110. Christoph T, Kogel B, Strassburger W, Schug SA. Tramadol has a better potency ratio relative to morphine in neuropathic than in nociceptive pain models. Drugs R D 2007; 8:51-57. (Pubitemid 46191807)
111. Ross FB, Wallis SC, Smith MT. Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side-effects in rats. Pain 2000; 84:421-428. (Pubitemid 30074246)
112. Bolan EA, Tallarida RJ, Pasternak GW. Synergy between mu opioid ligands: evidence for functional interactions among mu opioid receptor subtypes. J Pharmacol Exp Ther 2002; 303:557-562. (Pubitemid 35231226)
113. Smith MT. Differences between and combinations of opioids re-visited. Curr Opin Anaesthesiol 2008; 21:596-601.
114. Blumenthal S, Min K, Marquardt M, Borgeat A. Postoperative intravenous morphine consumption, pain scores, and side effects with perioperative oral controlled-release oxycodone after lumbar discectomy. Anesth Analg 2007; 105:233-237. (Pubitemid 46975870)
115. McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM. The nature, time course and severity of methamphetamine withdrawal. Addiction 2005; 100:1320-1329. (Pubitemid 41248073)
116. Berge KH, Morse RM. Protocol-driven treatment of alcohol withdrawal in a general hospital: when theory meets practice. Mayo Clin Proc 2008; 83:270-271. (Pubitemid 351469234)
117. Honey BL, Benefield RJ, Miller JL, Johnson PN. Alpha2-receptor agonists for treatment and prevention of iatrogenic opioid abstinence syndrome in critically ill patients. Ann Pharmacother 2009; 43:1506-1511.
118. Marinangeli F, Ciccozzi A, Donatelli F, Di Pietro A, Iovinelli G, Rawal N et al. Clonidine for treatment of postoperative pain: a dose-finding study. Eur J Pain 2002; 6:35-42.
119. Gabbard GO. Splitting in hospital treatment. Am J Psychiatry 1989; 146:444-451. (Pubitemid 19099293)
120. Morgan BD. Knowing how to play the game: hospitalized substance abusers' strategies for obtaining pain relief. Pain Manag Nurs 2006; 7:31-41. (Pubitemid 43257192)
121. Sim MG, Hulse GK, Khong E. Acute pain and opioid seeking behaviour. Aust Fam Physician 2004; 33:1009-1012.
122. May JA, White HC, Leonard-White A, Warltier DC, Pagel PS. The patient recovering from alcohol or drug addiction: special issues for the anesthesiologist. Anesth Analg 2001; 92:1601-1608. (Pubitemid 32493191)
123. Basu S, Bruce RD, Barry DT, Altice FL. Pharmacological pain control for human immunodeficiency virus-infected adults with a history of drug dependence. J Subst Abuse Treat 2007; 32:399-409. (Pubitemid 46661125)
124. Shaiova L, Berger A, Blinderman CD, Bruera E, Davis MP, Derby S et al. Consensus guideline on parenteral methadone use in pain and palliative care. Palliat Support Care 2008; 6:165-176.
125. Hagen NA, Moulin DE, Brasher PM, Biondo PD, Eliasziw M, Watanabe SM et al. A formal feasibility study of sublingual methadone for breakthrough cancer pain. Palliat Med 2010; 24:696-706.
126. Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract 2010; 10:428-450.
127. Roberts DM, Meyer-Witting M. High-dose buprenorphine: perioperative precautions and management strategies. Anaesth Intensive Care 2005; 33:17-25. (Pubitemid 40287592)
128. Kornfeld H, Manfredi L. Effectiveness of full agonist opioids in patients stabilized on buprenorphine undergoing major surgery: a case series. Am J Ther 2010; 17:523-528.
129. Russell R, Usher K, Macintyre PE. A comparison of postoperative opioid requirements and effectiveness in methadone- and buprenorphine-maintained patients. Anaesth Intensive Care 2011; 39:726-727.
130. Brown R, Kraus C, Fleming M, Reddy S. Methadone: applied pharmacology and use as adjunctive treatment in chronic pain. Postgrad Med J 2004; 80:654-659. (Pubitemid 39546060)
131. Kelly GA, Blake C, Power CK, O'Keeffe D, Fullen BM. The association between chronic low back pain and sleep: a systematic review. Clin J Pain 2011; 27:169-181.
132. Hutchinson MR, Loram LC, Zhang Y, Shridhar M, Rezvani N, Berkelhammer D et al. Evidence that tricyclic small molecules may possess toll-like receptor and myeloid differentiation protein 2 activity. Neuroscience 2010; 168:551-563.
133. Ho KY, Gan TJ, Habib AS. Gabapentin and postoperative pain - a systematic review of randomized controlled trials. Pain 2006; 126:91-101. (Pubitemid 44751958)
134. Hurley RW, Cohen SP, Williams KA, Rowlingson AJ, Wu CL. The analgesic effects of perioperative gabapentin on postoperative pain: a meta-analysis. Reg Anesth Pain Med 2006; 31:237-247.
135. Zhang J, Ho KY, Wang Y. Efficacy of pregabalin in acute postoperative pain: a meta-analysis. Br J Anaesth 2011; 106:454-462.
136. Vigneault L, Turgeon AF, Cote D, Lauzier F, Zarychanski R, Moore L et al. Perioperative intravenous lidocaine infusion for postoperative pain control: a meta-analysis of randomized controlled trials. Can J Anaesth 2011; 58:22-37.
137. Challapalli V, Tremont-Lukats IW, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst Rev 2005; CD003345.
138. Coyne PJ, Wozencraft CP, Roberts SB, Bobb B, Smith TJ. Dexmedetomidine: exploring its potential role and dosing guideline for its use in intractable pain in the palliative care setting. J Pain Palliat Care Pharmacother 2010; 24:384-386.
139. Ho KY, Tay W, Yeo MC, Liu H, Yeo SJ, Chia SL et al. Duloxetine reduces morphine requirements after knee replacement surgery. Br J Anaesth 2010; 105:371-376.
140. Australian Government, Department of Health and Ageing. Therapeutics goods administration. Contacts for State/Territory drugs & poisons units. From http://www.tga.gov.au/ndpsc/stdpu.htm Accessed February 2011.
141. Government of South Australia. Controlled Substances Act 1984. From http://www.legislation.sa.gov.au/LZ/C/A/CONTROLLED%20SUBSTANCES%20ACT%201984/ CURRENT/1984.52.UN.PDF Accessed February 2011.
142. Government of Western Australia. Poisons Act 1964. From http://www.slp.wa.gov.au/pco/prod/FileStore.nsf/Documents/MRDocument:20772P/ $FILE/PoisonsAct1964-08-i0-01.pdf?OpenElement Accessed January 2011.
143. Government of Western Australia. Poisons Regulations 1965. From http://www.slp.wa.gov.au/pco/prod/FileStore.nsf/Documents/MRDocument:20471P/ $FILE/PoisonsRegs1965-09-h0-00.pdf?OpenElement Accessed January 2011.
144. New Zealand Government. Misuse of Drugs Act 1975. From http://www.legislation.govt.nz/act/public/1975/0116/latest/DLM436101.html Accessed January 2011.
145. Government of South Australia. (1996) Controlled Substances (Poisons) Regulations 1996. From http://www.legislation.sa.gov.au/LZ/C/R/ CONTROLLED%20SUBSTANCES%20(POISONS)%20REGULATIONS%201996/CURRENT/1996.4.UN.PDF Accessed January 2011.
146. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings. From http://oas.samhsa.gov/NSDUH/2k9NSDUH/2k9ResultsP.pdf Accessed January 2011.
147. Jung B, Reidenberg MM. Physicians being deceived. Pain Med 2007; 8:433-437. (Pubitemid 47163281)
148. Passik SD, Kirsh KL. Screening for opioid abuse potential. IASP Pain Clinical Updates 2008; 16:1-4.
149. Meltzer EC, Rybin D, Saitz R, Samet JH, Schwartz SL, Butler SF et al. Identifying prescription opioid use disorder in primary care: diagnostic characteristics of the Current Opioid Misuse Measure (COMM). Pain 2011; 152:397-402.
150. Butler SF, Benoit C, Budman SH, Fernandez KC, McCormick C, Venuti SW. Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers. Harm Reduct J 2006; 3:5.
151. Schoedel KA, Sellers EM. Assessing abuse liability during drug development: changing standards and expectations. Clin Pharmacol Ther 2008; 83:622-626. (Pubitemid 351417064)
152. Raffa RB, Pergolizzi JV Jr. Opioid formulations designed to resist/deter abuse. Drugs 2010; 70:1657-1675.
153. Bandolier. Investigating over-the-counter oral analgesics. From http://www.medicine.ox.ac.uk/bandolier/booth/painpag/Acutrev/Analgesics/ OTC%20analgesics.html Accessed April 2010.
154. Frei MY, Nielsen S, Dobbin MD, Tobin CL. Serious morbidity associated with misuse of over-the-counter codeine-ibuprofen analgesics: a series of 27 cases. Med J Aust 2010; 193:294- 296.
155. World Health Organisation. WHO pain ladder. From http://www.who.int/ cancer/palliative/painladder/en/ Accessed January 2011.
156. McQuay H. Relief of chronic non-malignant pain. From http://www.medicine. ox.ac.uk/bandolier/booth/painpag/wisdom/493HJM.html Accessed May 2011.